CSI Market
Sign In | Register

Dmk Pharmaceuticals (DMK) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access DMK Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Dmk Pharmaceuticals's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-18.91
Depreciation & amortization0.26
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-0.02
Impairment of Leasehold0.12
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.58
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.08
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction-4.66
Common Stock Issued In Lieu Of Interest-
Stock Issued For Research Development Services-
Reduction Of Compensation Upon Forgiveness Of Accrued Bonus-
Amortization Of Stock Issued For Services-
Sales Returns Reserve Adjustment-
Conversion Of Gemini Interest-
Derivative Gain Loss On Derivative Net-
Stock Issued During Period Value Interest-
Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net-
Other Significant Noncash Transaction Value Of Consideration Given-
Stockissued-
A P I C Derivative Conversion Feature Liabilities-
Extinguishment Of Debt Gain Loss Net Of Tax-
Acquired I P R And D-
Gain On Repayment Of Contingent Loss Liability-
Increase Decrease In Product Recall Liability-
Gains On Forgiveness Of Debt-
Non Cash Operating Lease Expense-0.08
Increase Decrease In Product Recall Liabilities-0.31
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable1.05
Increase (Decrease) in Accounts Payable1.58
Increase (Decrease) in Other Accrued Liabilities1.11
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.32
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities9.02
Discontinued operations1.01
Net Cash flow from Operating Activities-7.85
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.01
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Businesses Gross-
Payments To Develop Website-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.14
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations2.60
Net Cash Flow from Investing Activities2.75
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock9.83
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.90
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.08
Proceeds From Warrant Conversion-
Cash Cash Equivalents And Short Term Investments-
Restricted Cash And Cash Equivalents-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Finance Lease Principal Payments-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations1.11
Change In Cash And Cash Equivalents Of Discontinued Operations-0.03
Payments Of Temporary Equity And Warrants Issuance Costs-
Payments Of Financing Issuance Costs-0.91
Proceeds From Common Warrant Exercises0.87
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.69
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.84
Total Cash Flow5.58
4 historic quarters locked

Sign in to unlock the full Dmk Pharmaceuticals cash flow history.

Sign In Create Free Account

About Dmk Pharmaceuticals Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001999371-23-000197

Figures are derived from filed reports and may be restated. Historical data is subject to revision.